David A. Sinclair

Career

Sinclair met Massachusetts Institute of Technology professor Leonard P. Guarente in 1993. Guarente had studied yeast as a model of aging, and after meeting him, Sinclair interviewed for a post-doc position in Guarente's lab.

Sirtris was focused on developing Sinclair's research into activators of sirtuins, work that began in the Guarente lab. The company went public in 2007 and was subsequently purchased by and made a subsidiary of GlaxoSmithKline in 2008 for $720 million. Five years later, GSK shuttered the Sirtris program without successful drug development.

In 2006, Sinclair co-founded Genocea Biosciences, a company founded based on the work of Harvard scientist Darren E. Higgins around antigens that stimulate T cells and the use of these antigens to create vaccines; The company delisted from the NASDAQ and closed in 2022 due to lack of funding.

In 2008, Sinclair was promoted to tenured professor at Harvard Medical School. In 2008, he also joined the scientific advisory board of Shaklee and helped them devise and introduce a product containing resveratrol called "Vivix". He later disputed the use of his name and words to promote the supplement, and resigned from the board.

In 2011, Sinclair co-founded OvaScience along with Michelle Dipp, Aldrich, Westphal, and Jonathan Tilly. The company was based on scientific work done by Tilly concerning mammalian oogonial stem cells and work on mitochondria by Sinclair. The company merged with Millendo Therapeutics in 2018. In 2011, he also co-founded CohBar along with Nir Barzilai and other colleagues. CohBar aimed to discover and develop novel peptides derived from mitochondria. CohBar delisted from the NASDAQ upon belief that it was a public shell.

In 2015, he co-founded Metro Biotech along with Washington University in St. Louis professor Dr. Rajendra Apte. The pharmaceutical company focused on NAD+ precursors such as NMN. He also co-founded Animal Bioscience in 2017 along with his brother Nick. The company focuses on small molecule-based therapy for the pet industry. In the same year he founded Life Biosciences to develop gene therapies aimed at age-related disease.

In 2022, Metro Biotech successfully urged the FDA to take actions to take NMN off the market as a supplement because Metro Biotech had registered NMN in investigational new drug applications. The following year, he co-founded Tally Health, a supplement company with a stated goal to "change the way we age" at the cellular level.

In 2024, Sinclair resigned as the President of The Academy for Health and Lifespan Research, an organization made up of a group of scientists that Sinclair had co-founded. The resignation came after what The Wall Street Journal described as a "cascade" of resignations from outraged members of The Academy after Sinclair and his brother announced that Animal Bioscience had proven that a supplement for dogs with undisclosed ingredients reversed aging. The claim was also met with criticism and skepticism from other longevity researchers.

While Sinclair was in Guarente's lab, he discovered that sirtuin 1 (called sir2 in yeast) slows aging in yeast by reducing the accumulation of extrachromosomal rDNA circles. Others working in the lab at the time identified NAD as an essential cofactor for sirtuin function. High-profile papers claiming age reversal of mice have also come under intense scrutiny. Sinclair's lab has continued to work on resveratrol and analogues of it as part of their research program in anti-aging. In 2023, with Bruce Ksander's lab at Mass Eye and Ear, they presented a poster at the annual ARVO conference accompanied by a company press release claiming that vision could be restored in non-human primates.

In January 2023, Sinclair's lab published research in Cell purporting to support his Information Theory of Aging, the idea that mammalian aging is due to the loss of epigenetic information, and that Yamanaka factors could exert a degree of artificial control over senescence and rejuvenation in mice. The paper received a formal reply pointing out that the treatment used in the paper is known to produce p53-dependent cell death in a 30-day period in which the mice were not observed. Sinclair's claims of reverse aging have received criticism from other scientists. This was also released as an audiobook on Audible and read by Sinclair. Sinclair broadly discusses his longevity practices on social media and includes them in his book. They include daily doses of nicotinamide mononucleotide (NMN) and resveratrol, which Sinclair claims are activators of SIRT1.

Selected publications 2023, The Information Theory of Aging, Nature Aging 2023, Chemically induced reprogramming to reverse cellular aging, Aging 2023, Loss of epigenetic information as a cause of mammalian aging, Cell 2021, The economic value of targeting aging, Nature Aging 2020, Reprogramming to recover youthful epigenetic information and restore vision, Nature 2008, SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging, Cell